Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 Jun;36(6):897–901. doi: 10.1136/gut.36.6.897

Significance of systemic endotoxaemia in inflammatory bowel disease.

K R Gardiner 1, M I Halliday 1, G R Barclay 1, L Milne 1, D Brown 1, S Stephens 1, R J Maxwell 1, B J Rowlands 1
PMCID: PMC1382629  PMID: 7615280

Abstract

Quantitative and qualitative disturbances in faecal flora suggest a role for enteric bacteria and their products in the pathogenesis of inflammatory bowel disease (IBD). This study investigated the hypothesis that systemically circulating endotoxins are of pathogenic significance in IBD by measuring antibody, cytokine, and acute phase protein responses. Systemic endotoxaemia was found in 88% patients with ulcerative colitis (n = 25) and 94% with Crohn's disease (n = 31) during clinical relapse. Systemic endotoxaemia correlated positively with anatomic extent and clinical activity of ulcerative colitis. Circulating tumour necrosis factor (TNF) was detected in 40% of patients with ulcerative colitis and 45% with Crohn's disease. Plasma TNF concentrations correlated with clinical and laboratory measures of disease activity and were associated with a surgical outcome to the disease episode. Plasma soluble TNF receptor p55 concentration correlated positively with disease activity and endotoxin core antibody concentrations. Plasma IgG endotoxin core antibody concentrations were significantly increased in patients with Crohn's disease and correlated with systemic endotoxaemia. The presence of systemic endotoxaemia, its correlation with disease activity, disease extent, and endotoxin core antibody concentration and the detection of circulating TNF and soluble TNF receptors all support a pathogenic role for endotoxins in IBD.

Full text

PDF
897

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki K. A study of endotoxemia in ulcerative colitis and Crohn's disease. I. Clinical study. Acta Med Okayama. 1978 Jun;32(2):147–158. [PubMed] [Google Scholar]
  2. Barclay G. R., Scott B. B. Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Infect Immun. 1987 Nov;55(11):2706–2714. doi: 10.1128/iai.55.11.2706-2714.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  4. Braegger C. P., Nicholls S., Murch S. H., Stephens S., MacDonald T. T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 Jan 11;339(8785):89–91. doi: 10.1016/0140-6736(92)90999-j. [DOI] [PubMed] [Google Scholar]
  5. Chikanza I. C., Roux-Lombard P., Dayer J. M., Panayi G. S. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol. 1993 Apr;92(1):19–22. doi: 10.1111/j.1365-2249.1993.tb05941.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colin R., Grancher T., Lemeland J. F., Hecketsweiler P., Galmiche J. P., Le Grix A., Geffroy Y. Recherche d'une endotoxinémie dans les entéro-colites inflammatoires cryptogénétiques. Gastroenterol Clin Biol. 1979 Jan;3(1):15–19. [PubMed] [Google Scholar]
  7. Cooke W. T., Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol. 1984 Feb;6(1):17–25. [PubMed] [Google Scholar]
  8. Engelberts I., Möller A., Schoen G. J., van der Linden C. J., Buurman W. A. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 1991 Apr;10(1-2):69–76. [PubMed] [Google Scholar]
  9. Fink P. C., Lehr L., Urbaschek R. M., Kozak J. Limulus amebocyte lysate test for endotoxemia: investigations with a femtogram sensitive spectrophotometric assay. Klin Wochenschr. 1981 Mar 2;59(5):213–218. doi: 10.1007/BF01476578. [DOI] [PubMed] [Google Scholar]
  10. Foley N., Lambert C., McNicol M., Johnson N., Rook G. A. An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol. 1990 Jun;80(3):395–399. doi: 10.1111/j.1365-2249.1990.tb03299.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fossard D. P., Kakkar V. V. The Limulus test in experimental and clinical endotoxaemia. Br J Surg. 1974 Oct;61(10):798–804. doi: 10.1002/bjs.1800611013. [DOI] [PubMed] [Google Scholar]
  12. Harvey R. F., Bradshaw J. M. A simple index of Crohn's-disease activity. Lancet. 1980 Mar 8;1(8167):514–514. doi: 10.1016/s0140-6736(80)92767-1. [DOI] [PubMed] [Google Scholar]
  13. Hotta T., Yoshida N., Yoshikawa T., Sugino S., Kondo M. Lipopolysaccharide-induced colitis in rabbits. Res Exp Med (Berl) 1986;186(1):61–69. doi: 10.1007/BF01851834. [DOI] [PubMed] [Google Scholar]
  14. Jenkins R. T., Jones D. B., Goodacre R. L., Collins S. M., Coates G., Hunt R. H., Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol. 1987 Nov;82(11):1159–1164. [PubMed] [Google Scholar]
  15. LeDuc L. E., Nast C. C. Chemotactic peptide-induced acute colitis in rabbits. Gastroenterology. 1990 Apr;98(4):929–935. doi: 10.1016/0016-5085(90)90017-u. [DOI] [PubMed] [Google Scholar]
  16. MacDonald T. T., Hutchings P., Choy M. Y., Murch S., Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990 Aug;81(2):301–305. doi: 10.1111/j.1365-2249.1990.tb03334.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Magliulo E., Scevola D., Fumarola D. Limulus test in Escherichia coli enteritis. Lancet. 1975 Feb 15;1(7903):407–407. doi: 10.1016/s0140-6736(75)91337-9. [DOI] [PubMed] [Google Scholar]
  18. Matthews N., Mayberry J. F., Rhodes J., Neale L., Munro J., Wensinck F., Lawson G. H., Rowland A. C., Berkhoff G. A., Barthold S. W. Agglutinins to bacteria in Crohn's disease. Gut. 1980 May;21(5):376–380. doi: 10.1136/gut.21.5.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mazlam M. Z., Hodgson H. J. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut. 1992 Jun;33(6):773–778. doi: 10.1136/gut.33.6.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Murch S. H., Lamkin V. A., Savage M. O., Walker-Smith J. A., MacDonald T. T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991 Aug;32(8):913–917. doi: 10.1136/gut.32.8.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. O'Dwyer S. T., Michie H. R., Ziegler T. R., Revhaug A., Smith R. J., Wilmore D. W. A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg. 1988 Dec;123(12):1459–1464. doi: 10.1001/archsurg.1988.01400360029003. [DOI] [PubMed] [Google Scholar]
  22. Parent K., Mitchell P. Cell wall-defective variants of pseudomonas-like (group Va) bacteria in Crohn's disease. Gastroenterology. 1978 Sep;75(3):368–372. [PubMed] [Google Scholar]
  23. Sartor R. B., Bond T. M., Schwab J. H. Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immun. 1988 Aug;56(8):2101–2108. doi: 10.1128/iai.56.8.2101-2108.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sartor R. B., Cromartie W. J., Powell D. W., Schwab J. H. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology. 1985 Sep;89(3):587–595. doi: 10.1016/0016-5085(85)90455-x. [DOI] [PubMed] [Google Scholar]
  25. Sturk A., van Deventer S. J., Wortel C. H., Levels J. H., ten Cate J. W., Büller H. R., Sanders G. T. Detection and clinical relevance of human endotoxemia. Z Med Lab Diagn. 1990;31(3):147–158. [PubMed] [Google Scholar]
  26. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tytgat G. N., Mulder C. J. The aetiology of Crohn's disease. Int J Colorectal Dis. 1986 Jul;1(3):188–192. doi: 10.1007/BF01648449. [DOI] [PubMed] [Google Scholar]
  28. Walker R. I., Porvaznik M. J. Disruption of the permeability barrier (zonula occludens) between intestinal epithelial cells by lethal doses of endotoxin. Infect Immun. 1978 Aug;21(2):655–658. doi: 10.1128/iai.21.2.655-658.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Warshaw A. L., Bellini C. A., Walker W. A. The intestinal mucosal barrier to intact antigenic protein. Difference between colon and small intestine. Am J Surg. 1977 Jan;133(1):55–58. doi: 10.1016/0002-9610(77)90193-3. [DOI] [PubMed] [Google Scholar]
  30. Wellmann W., Fink P. C., Benner F., Schmidt F. W. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut. 1986 Jul;27(7):814–820. doi: 10.1136/gut.27.7.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wensinck F., Custers-van Lieshout, Poppelaars-Kustermans P. A., Schröder A. M. The faecal flora of patients with Crohn's disease. J Hyg (Lond) 1981 Aug;87(1):1–12. doi: 10.1017/s0022172400069187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. van Deventer S. J., Buller H. R., ten Cate J. W., Sturk A., Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet. 1988 Mar 19;1(8586):605–609. doi: 10.1016/s0140-6736(88)91412-2. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES